<?xml version='1.0' encoding='utf-8'?>
<document id="25223698"><sentence text="Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates." /><sentence text="Monomethyl auristatin E (MMAE, a cytotoxic agent), upon releasing from valine-citrulline-MMAE (vc-MMAE) antibody-drug conjugates (ADCs), is expected to behave like small molecules"><entity charOffset="0-23" id="DDI-PubMed.25223698.s2.e0" text="Monomethyl auristatin E" /><entity charOffset="25-29" id="DDI-PubMed.25223698.s2.e1" text="MMAE" /><entity charOffset="89-92" id="DDI-PubMed.25223698.s2.e2" text="MMAE" /><entity charOffset="98-101" id="DDI-PubMed.25223698.s2.e3" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e0" e2="DDI-PubMed.25223698.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e0" e2="DDI-PubMed.25223698.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e0" e2="DDI-PubMed.25223698.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e0" e2="DDI-PubMed.25223698.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e1" e2="DDI-PubMed.25223698.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e1" e2="DDI-PubMed.25223698.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e1" e2="DDI-PubMed.25223698.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e2" e2="DDI-PubMed.25223698.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s2.e2" e2="DDI-PubMed.25223698.s2.e3" /></sentence><sentence text=" Therefore, evaluating the drug-drug interaction (DDI) potential associated with MMAE is important in the clinical development of ADCs"><entity charOffset="81-84" id="DDI-PubMed.25223698.s3.e0" text="MMAE" /></sentence><sentence text=" The objective of this work was to build a physiologically based pharmacokinetic (PBPK) model to assess MMAE-drug interactions for vc-MMAE ADCs"><entity charOffset="104-107" id="DDI-PubMed.25223698.s4.e0" text="MMAE" /><entity charOffset="134-137" id="DDI-PubMed.25223698.s4.e1" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.25223698.s4.e0" e2="DDI-PubMed.25223698.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25223698.s4.e0" e2="DDI-PubMed.25223698.s4.e1" /></sentence><sentence text="" /><sentence text="A PBPK model linking antibody-conjugated MMAE (acMMAE) to its catabolite unconjugated MMAE associated with vc-MMAE ADCs was developed using a mixed 'bottom-up' and 'top-down' approach"><entity charOffset="41-44" id="DDI-PubMed.25223698.s6.e0" text="MMAE" /><entity charOffset="49-52" id="DDI-PubMed.25223698.s6.e1" text="MMAE" /><entity charOffset="86-89" id="DDI-PubMed.25223698.s6.e2" text="MMAE" /><entity charOffset="110-113" id="DDI-PubMed.25223698.s6.e3" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e0" e2="DDI-PubMed.25223698.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e0" e2="DDI-PubMed.25223698.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e0" e2="DDI-PubMed.25223698.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e0" e2="DDI-PubMed.25223698.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e1" e2="DDI-PubMed.25223698.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e1" e2="DDI-PubMed.25223698.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e1" e2="DDI-PubMed.25223698.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e2" e2="DDI-PubMed.25223698.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s6.e2" e2="DDI-PubMed.25223698.s6.e3" /></sentence><sentence text=" The model was developed using in silico and in vitro data and in vivo pharmacokinetic data from anti-CD22-vc-MMAE ADC"><entity charOffset="110-113" id="DDI-PubMed.25223698.s7.e0" text="MMAE" /></sentence><sentence text=" Subsequently, the model was validated using clinical pharmacokinetic data from another vc-MMAE ADC, brentuximab vedotin"><entity charOffset="91-94" id="DDI-PubMed.25223698.s8.e0" text="MMAE" /></sentence><sentence text=" Finally, the verified model was used to simulate the results of clinical DDI studies between brentuximab vedotin and midazolam, ketoconazole, and rifampicin"><entity charOffset="118-127" id="DDI-PubMed.25223698.s9.e0" text="midazolam" /><entity charOffset="129-141" id="DDI-PubMed.25223698.s9.e1" text="ketoconazole" /><entity charOffset="147-157" id="DDI-PubMed.25223698.s9.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.25223698.s9.e0" e2="DDI-PubMed.25223698.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25223698.s9.e0" e2="DDI-PubMed.25223698.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s9.e0" e2="DDI-PubMed.25223698.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s9.e1" e2="DDI-PubMed.25223698.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s9.e1" e2="DDI-PubMed.25223698.s9.e2" /></sentence><sentence text="" /><sentence text="The pharmacokinetic profile of acMMAE and unconjugated MMAE following administration of anti-CD22-vc-MMAE was well described by simulations using the developed PBPK model"><entity charOffset="33-42" id="DDI-PubMed.25223698.s11.e0" text="MMAE" /><entity charOffset="55-64" id="DDI-PubMed.25223698.s11.e1" text="MMAE" /><entity charOffset="101-110" id="DDI-PubMed.25223698.s11.e2" text="MMAE" /><pair ddi="false" e1="DDI-PubMed.25223698.s11.e0" e2="DDI-PubMed.25223698.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25223698.s11.e0" e2="DDI-PubMed.25223698.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s11.e0" e2="DDI-PubMed.25223698.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25223698.s11.e1" e2="DDI-PubMed.25223698.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25223698.s11.e1" e2="DDI-PubMed.25223698.s11.e2" /></sentence><sentence text=" The model's performance in predicting unconjugated MMAE pharmacokinetics was verified by successful simulation of the pharmacokinetic profile following brentuximab vedotin administration"><entity charOffset="52-55" id="DDI-PubMed.25223698.s12.e0" text="MMAE" /></sentence><sentence text=" The model simulated DDIs, expressed as area under the concentration-time curve (AUC) and maximum concentration (C max) ratios, were well within the two-fold of the observed data from clinical DDI studies" /><sentence text="" /><sentence text="This work is the first demonstration of the use of PBPK modelling to predict MMAE-based DDI potential"><entity charOffset="77-80" id="DDI-PubMed.25223698.s15.e0" text="MMAE" /></sentence><sentence text=" The described model can be extended to assess the DDI potential of other vc-MMAE ADCs"><entity charOffset="77-80" id="DDI-PubMed.25223698.s16.e0" text="MMAE" /></sentence><sentence text="" /></document>